Toogood Andy
Division of Medical Sciences, Department of Medicine, Queen Elizabeth Hospital, University of Birmingham, Edgbaston, Birmingham, B15 2TH, UK.
Expert Opin Drug Saf. 2005 Nov;4(6):1069-82. doi: 10.1517/14740338.4.6.1069.
Limitless supplies of recombinant human growth hormone (GH) have been available for the last 20 years. During that period, studies have characterised the effects of GH deficiency in adults and the benefits of GH replacement therapy. Areas of greatest impairment and benefit are quality of life, skeletal health and cardiovascular risk factors including the serum lipid profile and body composition. By optimising GH replacement therapy at various stages of adult life, it is hoped that it will prevent the development of osteoporosis and reduce the mortality and morbidity associated with hypopituitarism. However, the primary indication for GH therapy in adults in England and Wales is quality of life. The benefits of GH treatment are sustained over several years, and long-term surveillance of patients continues.
在过去20年里，重组人生长激素（GH）一直有无限量供应。在此期间，多项研究已明确了成人生长激素缺乏的影响以及生长激素替代疗法的益处。受影响最大和受益最多的方面包括生活质量、骨骼健康以及心血管危险因素，如血脂谱和身体组成。通过在成年生活的各个阶段优化生长激素替代疗法，有望预防骨质疏松症的发生，并降低与垂体功能减退相关的死亡率和发病率。然而，在英格兰和威尔士，成人生长激素治疗的主要指征是生活质量。生长激素治疗的益处可持续数年，对患者的长期监测仍在继续。
